Oddball p53 in testicular tumors

Nature Medicine

Volumn 2, Issue 7, 1996, Pages 745-746

  Chresta, Christine M ^a   Hickman, John A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; PROTEIN P53;

DNA DAMAGE; HUMAN; PRIORITY JOURNAL; SEMINOMA; SHORT SURVEY; TERATOCARCINOMA; TESTIS TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA DAMAGE; DNA REPAIR; HUMANS; MALE; MICE; PHOSPHORYLATION; SEMINOMA; TERATOMA; TESTICULAR NEOPLASMS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029899837     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0796-745     Document Type: Short Survey

References (16)

1. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 253, 49-53 (1991).
2. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-52 (1993).
3. Bartkova, J. et al. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int. J. Cancer 49, 196-202 (1991).
4. Riou, G. et al. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog. 12, 124-131 (1995).
5. Peckham, M.J., Horwich, A. & Hendry, W.F. Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br. J. Cancer 52, 7-13 (1985).
6. Lutzker, S. & Levine, A.J. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med. 2, 804-810 (1996).
7. Hupp, T.R., Sparks, A. & Lane, D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237-45 (1995).
8. Canman, C.E., Gilmer, T.M., Coutts, S.B. & Kastan, M.B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 9, 600-611 (1995).
9. Barak, Y., Gottlieb, E., Juven, G.T. & Oren, M. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. 8, 1739-49 (1994).
10. Chresta, C.M., Masters, J.R.W. & Hickman, J.A. Hypersensitivity of human testicular tumours to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 56, 1834-1841 (1996).
11. Montes, d.O.L.R., Wagner, D.S. & Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206 (1995).
12. Hecker, D., Page, G., Lohrum, M., Weiland, S. & Scheidtmann, K.H. Complex regulation of the DNA-binding activity of p53 by phosphorylation: Differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene 12, 953-961 (1996).
13. Hall, S.R., Campbell, L.E. & Meek, D.W. Phosphorylation of p53 at the casein kinase site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res. 24, 1119-1126 (1996).
14. Hawkins, D.S., Demers, G.W. & Galloway, D.A. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56, 892-898 (1996).
15. Cordon, C.C. et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54, 794-799 (1994).
16. Fry, A.M. et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51, 6592-6595 (1991).